Growth Hormone Peptides: A Clinical Guide

Growth hormone peptides — also called GH secretagogues — are a class of compounds that share a single defining trait: rather than supplying growth hormone from outside the body, they prompt the patient's own pituitary gland to release it. That distinction separates them from injectable human growth hormone (HGH) and is the key to understanding both their appeal and their limits. This guide is written for clinicians who want an accurate, non-hyped map of the entire GH-axis class — what these peptides are, how they work, which compounds belong to it, and where each one stands legally.

Patients increasingly arrive having read marketing that outpaces the evidence, sometimes already sourcing "HGH peptides" from gray-market channels. Speaking to the class knowledgeably — including its limits and its evolving regulatory status — is part of practicing responsibly in anti-aging and regenerative medicine. This is clinical education, not medical advice.

What growth hormone peptides are — and how they differ from HGH

The single most important idea in this entire class is the difference between amplifying a hormone signal and replacing one. Injectable human growth hormone floods the system with hormone manufactured outside the body. It bypasses the pituitary entirely, suppresses the feedback axis, and produces supraphysiologic GH and IGF-1 levels that a clinician then has to manage downward. It also carries meaningful regulatory exposure — exogenous HGH is a controlled substance with DEA-monitored prescribing, and off-label use carries significant risk. For most aesthetic and longevity practices, it belongs in endocrinology, not on the prescription pad.

Growth hormone peptides take the opposite approach. They stimulate the body's own pulsatile GH release, working within the physiologic feedback system rather than around it. Because the pituitary stays in charge, endogenous somatostatin can still brake secretion when GH rises too high — a self-limiting safeguard that direct HGH administration removes. The result is a more modest, more pulsatile IGF-1 elevation that is easier to titrate and monitor. The honest framing is that these compounds are a pituitary optimizer, not a GH replacement: they amplify the pulses the patient is still capable of making. That single sentence resolves most patient questions about safety and long-term use.

The GH/IGF-1 axis

To understand any compound in this class, you have to understand the axis it acts on. Growth hormone is secreted by somatotroph cells in the anterior pituitary, and it is released not as a steady infusion but in pulsatile bursts — predominantly during slow-wave sleep and after exercise. The hypothalamus governs the timing of those pulses through two opposing signals: GHRH (growth-hormone-releasing hormone), which stimulates release, and somatostatin, which inhibits it. A pulse occurs when the GHRH signal wins. That pulsatility is the most important physiologic concept in the growth hormone world, and every peptide in this class is built to respect it.

Here is the part clinicians most often miss: GH itself has limited direct anabolic effect — it is largely a messenger. The downstream tissue effects are mediated by insulin-like growth factor 1 (IGF-1), which the liver produces in response to GH. The cascade runs pituitary → GH → liver-derived IGF-1 → tissue effect, and IGF-1 is what drives protein synthesis, satellite-cell activation (muscle repair), lipolysis in adipose tissue, collagen synthesis, and bone remodeling. That distinction is not academic: IGF-1, not GH, is what clinicians actually measure, because the short, pulsatile GH signal is difficult to capture on a single blood draw.

The clinical rationale rests on the age trajectory of the axis. GH secretion peaks at puberty and declines with age — roughly half of peak by the forties and lower still by the sixties — a normal physiologic process sometimes called somatopause. Importantly, somatopause is not a disease state. The honest framing is not that a patient has a deficiency requiring replacement, but that an age-related decline in a normal axis is being gently optimized — a distinction that carries real ethical and regulatory weight.

The axis also explains why combining compounds matters. The pituitary carries co-receptors for two separate inputs: the GHRH receptor and the ghrelin / growth hormone secretagogue receptor (GHSR). Activating both at once produces a GH pulse substantially larger than the sum of the two acting alone — a synergistic, not additive, effect. That single piece of physiology is the entire rationale behind pairing a GHRH analog with a ghrelin mimetic.

The compounds in the class

The growth hormone peptides fall into two functional categories defined by which receptor they act on, plus one mechanistically distinct outlier. Each compound below has its own dedicated clinical guide.

GHRH analogs (signal one)

These peptides mimic growth-hormone-releasing hormone and bind the GHRH receptor, priming the pituitary to synthesize and release GH.

• Sermorelin — a truncated 29-amino-acid fragment of GHRH and the historically original synthetic GHRH analog. Its short half life closely mimics the body's natural pulse, and its prior FDA approval gives it special regulatory standing today.
• Tesamorelin — a synthetic analog of full-length GHRH and the only FDA-approved GHRH analog currently on the market, with the longest track record and most robust human evidence base in the class.
• CJC-1295 — a longer-acting GHRH analog engineered to resist enzymatic degradation. The pulse-preserving "no-DAC" version is generally preferred; the albumin-bound DAC version trades pulsatility for convenience and is widely discouraged. Covered alongside ipamorelin in the Ipamorelin & CJC-1295 guide.

Ghrelin mimetics (signal two)

These peptides mimic ghrelin and bind the GHSR receptor, amplifying GH pulse amplitude.

• Ipamorelin — a selective ghrelin mimetic that, unlike older secretagogues, does not meaningfully raise cortisol, prolactin, or ACTH. Its clean receptor selectivity is why it appears in nearly every classic stack and can be combined with a GHRH analog in a single pre-sleep injection.

A mechanistically distinct fragment

• AOD-9604 — a fragment of the C-terminus of growth hormone (residues 176–191), the portion responsible for fat metabolism. It acts on adipose tissue to promote lipolysis without binding GH receptors, so it does not raise IGF-1 or affect glucose. It carries no anabolic signal and is best understood as a stack-friendly adjunct rather than a primary compound.

The 2026 regulatory map

Few areas of peptide practice are more consequential — or more frequently gotten wrong — than the regulatory status of this class. The picture is genuinely uneven across compounds, and a clinician has to know exactly where each one sits.

Tesamorelin remains FDA-approved as a branded product for the reduction of excess abdominal fat in HIV-associated lipodystrophy. That is a narrow indication backed by strong randomized controlled trial data; off-label use in non-HIV body-composition contexts is common but requires informed consent documenting the off-label nature.

Sermorelin occupies a special position. A branded product (Geref) was previously FDA-approved but has since been discontinued, and sermorelin is now generally obtained through compounding pharmacies. Crucially, that prior approval confers a special status that, in 2026, makes sermorelin one of the cleanest 503A compounding paths in the entire class.

CJC-1295, ipamorelin, and AOD-9604 tell a different story. Each was removed from FDA compounding category 2, but removal alone does not create a lawful compounding path — it merely opens the door to review by the Pharmacy Compounding Advisory Committee (PCAC). In late 2024, PCAC voted against all three. The practical consequence is that these compounds currently have no 503A compounding pathway, and protocols citing them today generally describe products without a legitimate U.S. route — meaning gray-market or non-compliant pharmacy sourcing.

IGF-1 monitoring & patient selection

Mechanism and regulatory status answer what these compounds are. The harder clinical questions are who is a reasonable candidate and what gets monitored — and this is where real-world practice succeeds or fails.

The archetypal candidate is an adult, often in their forties through sixties, already training and eating well, who wants to optimize body composition, recovery, sleep, or connective-tissue resilience. These are not weight-loss drugs and not the same patients who belong on a GLP-1 agonist. Before reaching for any GH secretagogue, a careful clinician first rules out the conditions that mimic somatopause symptoms — hypothyroidism, depression, sleep apnea, and low testosterone — because amplifying the GH axis will not fix a problem that lives elsewhere.

Just as important is knowing who is not a candidate. Because GH and IGF-1 are mitogenic — they drive cell division — active or recent malignancy is a hard contraindication, and any history of hormone-sensitive cancer warrants oncology input before initiating. Other clear exclusions include acromegaly or any GH-excess condition, active carpal tunnel syndrome (which GH signaling can worsen), pregnancy and breastfeeding, and pediatric patients, whose still-developing axis belongs in endocrinology. A baseline IGF-1 already at or above the age-appropriate reference range is also a reason to hold: the goal is to support a declining axis, not push one that is already at the top of normal. Poorly controlled diabetes and diabetic retinopathy are additional cautions, since GH is an insulin antagonist and can influence neovascularization.

Monitoring centers on IGF-1, the measurable downstream marker of the cascade. Responsible practice means a baseline IGF-1 before starting — with fasting glucose and an A1c for patients with diabetes risk — and a follow-up IGF-1 several weeks in to confirm the response sits within, not above, the age-appropriate range. The aim is a modest, physiologic elevation; a level drifting into supraphysiologic territory is a signal to step the dose back, not push on. One notable exception is AOD-9604, which does not raise IGF-1 and therefore does not require IGF-1 monitoring in the same way. (Exact lab targets, intervals, and dosing decisions are covered in depth in Empire's Peptide Therapy Master Course.)

Realistic timelines

The most consequential conversation in this entire class happens at initiation, and it is about time. Patients want to feel results in four weeks; the biology of GH optimization runs on a six-month-plus horizon. That gap between expectation and physiology is where protocols most often fail — not because the compound did nothing, but because the patient stopped before it had time to work.

A few checkpoints are worth walking patients through with intention. The earliest reproducible improvement most patients notice is better, more restorative sleep, often within the first few weeks — a useful early signal that the protocol is engaging the axis. Body-composition change typically becomes visible considerably later. The connective-tissue benefits that justify therapy for many athletes — tendon resilience, joint comfort, faster recovery between sessions — tend to emerge over several months, and the durable trajectory shift in body composition and energy shows up across a year and beyond. A clinician who frames the class honestly at the outset, names the early sleep checkpoint, and defends the longer timeline through the slow stretch is far more likely to have the patient who actually reaches the outcome. GH optimization is a marathon, not a quarterly cycle.

Provider training

Sound peptide education does not begin and end with a list of compounds. For a class like the growth hormone peptides, the most valuable thing a clinician can learn is how to reason about it honestly: how a secretagogue differs from direct HGH therapy, how a GHRH analog differs from a ghrelin mimetic, how to read the limits of the evidence, how to interpret a regulatory map that ranges from FDA-approved to PCAC-rejected, and how to communicate realistic, months-long timelines without overpromising.

Empire's peptide curriculum is built around that kind of clinical judgment. It situates each compound within the broader science of peptide therapy, teaches evidence interpretation and compliant sourcing, and is part of the larger Academy of Anti-Aging & Functional Medicine. For a foundational overview, providers often start with what peptide therapy is before going deeper into individual GH-axis compounds such as sermorelin and tesamorelin.